Breakthrough Treatments for Metabolic Syndrome

Learn More
Learn more about Diamedica

About Diamedica

DiaMedica Inc. is a publicly traded clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes.

About Diamedica
Learn more about Diamedica

Product Pipeline

DiaMedica’s lead clinical stage product, DM199, is a recombinant human protein to treat diabetes and associated complications. DMDx is a companion diagnostic assay to predict the rate of progression towards end-stage kidney disease. DM204 is a novel monoclonal antibody for the treatment of type 2 diabetes.

View Pipeline ›